| FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL V Close, W Close, SJ Kugler, M Reichenzeller, DY Yosifov, J Bloehdorn, ... Blood, The Journal of the American Society of Hematology 133 (8), 830-839, 2019 | 77 | 2019 |
| From biology to therapy: the CLL success story DY Yosifov, C Wolf, S Stilgenbauer, D Mertens Hemasphere 3 (2), e175, 2019 | 70 | 2019 |
| Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues BS Hanna, PM Roessner, H Yazdanparast, D Colomer, E Campo, ... Leukemia 33 (3), 625-637, 2019 | 69 | 2019 |
| Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1 E Tausch, P Beck, RF Schlenk, BMC Jebaraj, A Dolnik, DY Yosifov, ... haematologica 105 (10), 2440, 2020 | 39 | 2020 |
| Erucylphospho-N,N,N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity DY Yosifov, PT Todorov, MM Zaharieva, KD Georgiev, BA Pilicheva, ... Cancer chemotherapy and pharmacology 67, 13-25, 2011 | 37 | 2011 |
| Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL DY Yosifov, I Idler, N Bhattacharya, M Reichenzeller, V Close, D Ezerina, ... Leukemia 34 (1), 115-127, 2020 | 28 | 2020 |
| Alkylphosphocholines and curcumin induce programmed cell death in cutaneous T-cell lymphoma cell lines DY Yosifov, KA Kaloyanov, ML Guenova, K Prisadashka, MB Balabanova, ... Leukemia Research 38 (1), 49-56, 2014 | 27 | 2014 |
| Erucylphospho-N,N,N-trimethylpropylammonium shows substantial cytotoxicity in multiple myeloma cells DY Yosifov, SM Konstantinov, MR Berger Natural Compounds and Their Role in Apoptotic Cell Signaling Pathways 1171 …, 2009 | 21 | 2009 |
| Interleukin-6, osteopontin and Raf/MEK/ERK signaling modulate the sensitivity of human myeloma cells to alkylphosphocholines DY Yosifov, C Reufsteck, SM Konstantinov, MR Berger Leukemia research 36 (6), 764-772, 2012 | 15 | 2012 |
| Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo (immune) therapy M Zapatka, E Tausch, S Öztürk, DY Yosifov, M Seiffert, T Zenz, ... Haematologica 107 (3), 604, 2022 | 13 | 2022 |
| Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany) Y Ilieva, K Kaloyanov, D Yosifov, B Robev, I Zhelezova, M Genova, ... Phytochemistry reviews 13, 459-469, 2014 | 13 | 2014 |
| Cytotoxicity of gypsogenic acid isolated from Gypsophila trichotoma I Krasteva, M Yotova, D Yosifov, N Benbassat, K Jenett-Siems, ... Pharmacognosy Magazine 10 (Suppl 2), S430, 2014 | 11 | 2014 |
| Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations E Tausch, V Ljungström, A Agathangelidis, M Zapatka, L Scarfò, ... Blood, The Journal of the American Society of Hematology 139 (22), 3340-3344, 2022 | 9 | 2022 |
| Genetic markers and outcome with front line obinutuzumab plus either chlorambucil or venetoclax-updated analysis of the CLL14 trial E Tausch, C Schneider, D Yosifov, S Robrecht, C Zhang, O Al-Sawaf, ... Hematol Oncol 39, 2021 | 9 | 2021 |
| Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors J Qi, S Endres, DY Yosifov, E Tausch, RP Dheenadayalan, X Gao, ... Blood advances 7 (19), 5698-5702, 2023 | 8 | 2023 |
| The expression level of the tumor suppressor retinoblastoma protein (Rb) influences the antileukemic efficacy of erucylphospho-N, N, N-trimethylpropylammonium (ErPC3) DY Yosifov, IK Dineva, MM Zaharieva, SM Konstantinov, MR Berger Cancer biology & therapy 6 (6), 930-935, 2007 | 8 | 2007 |
| DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy DY Yosifov, J Bloehdorn, H Döhner, P Lichter, S Stilgenbauer, D Mertens Scientific data 7 (1), 133, 2020 | 7 | 2020 |
| A particular expression pattern of CD13 epitope 7H5 in chronic lymphocytic leukaemia - a possible new therapeutic target ML Guenova, A Michova, GN Balatzenko, DY Yosifov, N Stoyanov, ... Hematology 17 (3), 132-139, 2012 | 5 | 2012 |
| Genetic markers and front line FCR/BR vs. rve, gve and give treatment-outcome results from the CLL13/GAIA trial E Tausch, C Schneider, M Furstenau, S Robrecht, DY Yosifov, D Mertens, ... Blood 140 (Supplement 1), 839-841, 2022 | 4 | 2022 |
| NOTCH1 signaling is activated in CLL by mutations of FBXW7 and low expression of USP28 at 11q23 V Close, W Close, SJ Kugler, M Reichenzeller, DY Yosifov, J Bloehdorn, ... Blood 132, 946, 2018 | 3 | 2018 |
Bola HannaGenentechVerified email at gene.com
